During the past decade, Albuquerque Clinical Trials, Inc. conducted 72 clinical trials. In the 10-year time frame, 72 clinical trials started and 68 clinical trials were completed, i.e. on average, 94.4% percent of trials that started reached the finish line to date. In the past 5 years, 33 clinical trials started and 46 clinical trials were completed. i.e. 139.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Albuquerque Clinical Trials, Inc." #1 sponsor was "Pfizer" with 19 trials, followed by "Eli Lilly and Company" with 14 trials sponsored, "Allergan" with 5 trials sponsored, "Bristol-Myers Squibb" with 5 trials sponsored and "Gilead Sciences" with 5 trials sponsored. Other sponsors include 49 different institutions and companies that sponsored additional 47 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Albuquerque Clinical Trials, Inc." #1 collaborator was "CoLucid Pharmaceuticals" with 2 trials as a collaborator, "Incyte Corporation" with 2 trials as a collaborator, "PPD" with 2 trials as a collaborator, "Alder Biopharmaceuticals, Inc." with 1 trials as a collaborator and "Eli Lilly and Company" with 1 trials as a collaborator. Other collaborators include 8 different institutions and companies that were collaborators in the rest 18 trials.

According to Clinical.Site data, the most researched conditions in "Albuquerque Clinical Trials, Inc." are "Migraine" (18 trials), "Rheumatoid Arthritis" (11 trials), "Arthritis" (5 trials), "Low Back Pain" (5 trials) and "Osteoarthritis" (5 trials). Many other conditions were trialed in "Albuquerque Clinical Trials, Inc." in a lesser frequency.

Most popular intervention types in "Albuquerque Clinical Trials, Inc." are "Drug" (91 trials), "Biological" (14 trials), "Other" (12 trials), "Behavioral" (3 trials) and "Dietary Supplement" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (52 trials), "Galcanezumab" (6 trials), "Baricitinib" (4 trials), "placebo" (4 trials) and "Atogepant" (3 trials). Other intervention names were less common.

The vast majority of trials in "Albuquerque Clinical Trials, Inc." are 93 trials for "All" genders and 9 trials for "Female" genders.

Currently, there are NaN active trials in "Albuquerque Clinical Trials, Inc.". undefined are not yet recruiting, 8 are recruiting, 5 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 78 completed trials in Albuquerque Clinical Trials, Inc., 1 suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Albuquerque Clinical Trials, Inc., 1 "Phase 1" clinical trials were conducted, 35 "Phase 2" clinical trials and 65 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 0 trials that are defined as “Not Applicable".